CMT-8/clodronate combination therapy synergistically inhibits alveolar bone loss in LPS-induced periodontitis.
Llavaneras
A
A
Department of Oral Biology and Pathology, School of Dental Medicine, State University of New York at Stony Brook 11794-8702, USA.
Golub
L M
LM
Rifkin
B R
BR
Heikkilä
P
P
Sorsa
T
T
Teronen
O
O
Salo
T
T
Liu
Y
Y
Ryan
M E
ME
Ramamurthy
N S
NS
D016301:Alveolar Bone Loss / Q000517:prevention & control*; D000818:Animals; D004002:Clodronic Acid / Q000627:therapeutic use*; D017364:Collagenases / Q000378:metabolism; D004357:Drug Synergism; D004359:Drug Therapy, Combination; D018093:Gelatinases / Q000378:metabolism; D005881:Gingiva / Q000201:enzymology; D008070:Lipopolysaccharides / Q000633:toxicity*; D008297:Male; D010518:Periodontitis / Q000139:chemically induced / Q000150:complications / Q000503:physiopathology*; D011480:Protease Inhibitors / Q000627:therapeutic use*; D051381:Rats; D017207:Rats, Sprague-Dawley; D013754:Tetracyclines / Q000627:therapeutic use*; D014086:Tooth Mobility / Q000517:prevention & control
D008070:Lipopolysaccharides; D011480:Protease Inhibitors; D013754:Tetracyclines; C117153:tetracycline CMT-8; D004002:Clodronic Acid; D017364:Collagenases; D018093:Gelatinases